



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

11 Jan 2017 (#1)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- **Webinar for Revision Applications for U.S-South African Program for Collaborative Biomedical Research (R01 and U01)**. A webinar will be held on **18 January 2017 at 15h00 to 17h00**. Venues at the SAMRC Cape Town and Pretoria offices will broadcast the webinar. Limited space is available; if you would like to reserve a seat, please advise by email to arlene.smith@mrc.ac.za. Kindly forward questions related to FOAs timeously so that they can be addressed during the webinar. The webinar link and login details will be made available closer to the time. Participants can participate in the webinar via their workstations/laptops.

Please join my meeting from your computer, tablet or smartphone: <https://global.gotomeeting.com/join/992524509>

You can also dial in using your phone: United States: +1 (571) 317-3112

Access Code: 992-524-509 First GoToMeeting? Try a test session: <http://help.citrix.com/getready>

The first hour will cover the following five topics followed by a 30 min Q&A.

- 1) Background of MRC-NIH Joint Research Program. Intent & Expectations for Supplemental Funding Opportunity
- 2) Current Funding Opportunity Overview
- 3) Grants Management
- 4) Peer Review
- 5) What Makes a Good Collaboration

- **NIH & AHRQ Update Font Guidelines for Applications to Due Dates On or After January 25, 2017 (NOT-OD-17-030)** text in PDF attachments must follow these minimum requirements:

Text Color: No restriction. Though not required, black or other high-contrast text colors are recommended since they print well and are legible to the largest audience.

Font size: Must be 11 points or larger. Smaller text in figures, graphs, diagrams and charts is acceptable, as long as it is legible when the page is viewed at 100%.

Type density: Must be no more than 15 characters per linear inch (including characters and spaces).

Line spacing: Must be no more than six lines per vertical inch (Single spacing)

Font Type: The following font is recommended, Arial

Since some PDF converters may reduce font size, it is important to confirm that the final PDF document complies with the font requirements. Legibility is of paramount importance. Applications that include PDF attachments that do not conform to the minimum requirements listed above may be withdrawn from consideration.

1. Revision Applications for U.S-South Africa Program for Collaborative Biomedical Research

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-16-082\)](#)

Type: R01

Application Due Date: March 28, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (R01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.

Budget: Application budgets are limited to \$250,000 per year in total costs for up to two years. Applicants must have at least one year of funding remaining on their grant at the time of submission. A minimum of 67% of the total cost budget should be apportioned to activities that will be conducted in South Africa. Indirect cost for foreign grantees are limited to 8%. F&A costs requested by consortium participants are not included in the direct cost limitation. Awards will be made as revisions to the parent R01 and cannot exceed the project period of the parent award.

2. Revision Applications for U.S.-South Africa Program for Collaborative Biomedical Research

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-16-083\)](#)

Type: U01

Application Due Date: March 28, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (U01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.

Budget: Application budgets are limited to \$250,000 per year in total costs for up to two years, inclusive of the limit of \$50,000 per year to support the NIH Intramural investigator's costs attributed to the proposed revision activities. A minimum of 67% of the total cost budget should be apportioned to activities that will be conducted at South African institutions. Applicants may request support for up to 2 years. At the time of award of the revision, there must be two years remaining on the parent award for a two year revision request or one year remaining on the parent award for a one year revision request. Awards will be made as revisions to the parent U01 and cannot exceed the project period of the parent award.

3. Pilot Clinical Trials Targeting HIV-1 Reservoirs in Children

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-16-086\)](#)

Type: U01

Application Due Date: March 14 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to support pilot clinical trials that test interventions to limit or reduce HIV-1 reservoirs in children (birth to 18 years of age at the time of enrollment) on effective suppressive antiretroviral therapy.

Budget: NIAID intends to commit \$ 3,150,000 in FY2018 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period may not exceed 5 years.

4. Implementation Science for the Prevention and Treatment of Mental and/or Substance use Disorders in Low- and Middle-income Countries

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-MH-17-650\)](#)

Type: U01

Application Due Date: April 7, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) solicits grant applications to address implementation research questions facing World Bank designated low- and middle-income countries (LMICs) and previously designated LMICs re-categorized as high income on or after January 1, 2011, in their efforts to deliver sustainable, evidence-based interventions for the prevention, early intervention, and treatment of mental and/or substance use disorders in women, men, and children. Each awarded project is to conduct implementation research in one of six geographical regions (i.e., East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa). As a group, awardees will constitute a network for mental and behavioral health implementation research in low-resource settings with capabilities for answering research questions about delivering interventions, sustaining high-quality care in resource-limited settings, and fostering evidence-based policy and program development for preventing and/or treating mental and/or substance use disorders. This program is not intended to support research that can be conducted primarily in and/or by the United States or other high-income country institutions that do not meet eligibility criteria.

Budget: The following NIH components intend to commit the following amounts in FY 2018: NIMH, \$2,500,000, 3-4 awards; NIDA, \$500,000, 1-2 awards. Application budgets are limited to \$425,000 direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Fertility Status as a Marker for Overall Health

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-091\)](#)
[\(PA-17-092\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program.

Budget: R01: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

6. Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-093\)](#)

Type:

Application Due Date: March 1, 2017; June 7, 2017; October 3, 2017; March 1, 2018; June 7, 2018; October 3, 2018; March 1, 2019; June 7, 2019; October 3, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem. The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

7. Planning for Non-Communicable Diseases and Disorders Research Training Programs in Low and Middle Income Countries

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-097\)](#)

Type: D71

Application Due Date: March 14, 2017; March 14, 2018; March 14, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) for research training program planning invites submissions from low- and middle-income country (LMIC) institution(s) with existing research and research training capacity in chronic, non-communicable diseases and disorders (NCDs). These institutions must propose to assess needs and develop a plan for a research training program within the LMIC(s) that will further strengthen the capacity of LMIC individuals, institution(s) and country(ies) to identify NCD priorities and conduct NCD research across the lifespan. The application from the LMIC institution(s) may include collaboration with United States (U.S) institutions and other LMIC institutions as justified and appropriate.

Budget: Application budgets are limited \$46,000 (total direct costs). The maximum project period is 1 year.

8. HIV-1 infection of the Central Nervous System

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-100\)](#)

Type: R01

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) invites research grant applications focused on defining and understanding the pathogenic mechanisms involved in Human Immunodeficiency Virus (HIV)-1 induced CNS dysfunction, but within the context of viral suppression and Antiretroviral therapy (ART). The FOA further supports research to identify therapeutic targets against which treatments may be developed to prevent the neurobehavioral and neurological co-morbidities in HIV-1 infected individuals. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. National Institute of Neurological Disorders and Stroke Efficacy Clinical Trials

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-102\)](#)

Type: U01

Application Due Date: March 21, 2017 then [Standard dates](#) For Aids: May 7, 2017 then [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<http://www.ninds.nih.gov/>)

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum request cannot exceed 5 years.

10. Systems Biology: The Next Generation for Infectious Diseases

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-16-080\)](#)

Type: U19

Application Due Date: March 15, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) solicits applications to establish Systems Biology Centers that use systems biology approaches to build predictive models for infectious diseases. These models will be derived from hypotheses related to systems-level host/pathogen molecular interactions during infection or treatment using integrated datasets generated from a combination of high-throughput experimental approaches, including omics technologies and computational approaches. Importantly, the Centers must clearly integrate experimental approaches and computational modeling to test and validate hypotheses of significance to the infectious diseases field.

Budget: NIAID intends to commit \$11 million in FY2018 to fund up to 5 awards. Budgets for direct costs of up to \$2,000,000 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)

